Program
pegcetacoplan
Also written as “Pegcetacoplan”, “APL-2” and “PEGCETACOPLAN (APL-2)”.
Its studies are mostly in Geographic Atrophy · Hemoglobinuria, Paroxysmal · Glomerulonephritis, Membranoproliferative · Anemia, Hemolytic, Autoimmune · Macular Degeneration, led by 4 companies.
Drug pagePegcetacoplan: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 244 open or running | phase 3since Apr 10, 2018 | Oct 8, 2014 | Jun 25, 2027phase 2 · NCT07215390 |
| Swedish Orphan Biovitrumits history only | 42 open or running | phase 4since Mar 26, 2026 | Oct 15, 2021 | Jan 17, 2031phase 3 · NCT07898774 |
| AbbVieits history only | 11 open or running | phase 2since Aug 12, 2025 | Aug 12, 2025 | Oct 2029phase 2 · NCT07160179 |
| Hoffmann-La Rocheits history only | 10 open or running | phase 1since Apr 29, 2025 | Apr 29, 2025 | none ahead |
Also a collaborator on its studies: IQVIA Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Biogen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 7 earlier studies, Oct 8, 2014 to Mar 8, 2018.
- Dec 9, 2017Named pegcetacoplanINNProposed as its International Nonproprietary Name in WHO's List 118
- Apr 10, 20183 phase 3 studiesNCT03500549, NCT03525613, NCT03525600
- May 9, 2018Phase 3 study in PNHNCT03531255 · 137 enrolled · United States, Australia, Belgium and more
- Jun 28, 2018Phase 2 study in Hemoglobinuria, ParoxysmalNCT03593200 · 4 enrolled · Bulgaria, Serbia
- Dec 14, 2018Phase 1 study in Geographic AtrophyNCT03777332 · 19 enrolled · United States
- Sep 9, 2019Phase 3 study in Hemoglobinuria, ParoxysmalNCT04085601 · 53 enrolled · Colombia, Hong Kong, Malaysia and more
- Sep 22, 20202 phase 2 studiesNCT04579666, NCT04572854
- Feb 23, 2021Phase 3 study in Geographic Atrophy Secondary to Age-related Macular DegenerationNCT04770545 · 792 enrolled · United States, Argentina, Australia and more
- Mar 8, 2021Phase 2 study in Hemoglobinuria, ParoxysmalNCT04901936 · 12 planned · United States, Czechia, France and more
- Sep 23, 2021Phase 3 study in Glomerulonephritis, MembranoproliferativeNCT05067127 · 124 enrolled · United States, Argentina, Australia and more
- Mar 30, 2023Phase 3 study in Glomerulonephritis, MembranoproliferativeNCT05809531 · 100 enrolled · United States, Argentina, Australia and more
- Jun 6, 2025Phase 3 study in Delayed Graft FunctionNCT07020832 · Brazil
- Jun 30, 2025Phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationNCT07215390 · 240 planned · United States
- Sep 15, 2025Phase 3 study in FSGSNCT07213960 · 270 planned · United States
- Oct 6, 2025Phase 3 study in Geographic AtrophyNCT07214740 · 44 enrolled · United States
Ahead
- Jun 25, 2027Primary completion: phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationNCT07215390
- Jul 2027Primary completion: phase 3 study in Glomerulonephritis, MembranoproliferativeNCT05809531
- Dec 2028Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT04901936
- Oct 2029Primary completion: phase 3 study in FSGSNCT07213960
TargetBeta
“A pegylated peptide inhibitor of human complement components C3 and C3b, ”NCIt, by rule
“Complement C3 inhibitor”ChEMBL 37, by rule
Other programs on C3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| SSS55rule | 3SBio | phase 1 | 1 |
Studies
All 24 Biogen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07214740Geographic Atrophy · United States | 3 | Completed | Dec 12, 2025 | 44 |
| NCT07213960FSGS · United States | 3 | Recruiting | Oct 2029 | 270 |
| NCT07215390Geographic Atrophy Secondary to Age-related Macular Degeneration · United States | 2 | Recruiting | Jun 25, 2027 | 240 |
| NCT07020832Delayed Graft Function · Brazil | 3 | Withdrawn | Jun 2029 | 0 |
| NCT05809531Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 2027 | 100 |
| NCT05067127Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more | 3 | Completed | Jun 26, 2024 | 124 |
| NCT04901936Hemoglobinuria, Paroxysmal · United States, Czechia, France and more | 2 | Recruiting | Dec 2028 | 12 |
| NCT04770545Geographic Atrophy Secondary to Age-related Macular Degeneration · United States, Argentina, Australia and more | 3 | Completed | Sep 5, 2025 | 792 |
| NCT04572854Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more | 2 | Completed | Feb 27, 2023 | 13 |
| NCT04579666Amyotrophic Lateral Sclerosis · United States, Australia, Belgium and more | 2 | Terminated | Mar 31, 2023 | 249 |
| NCT04085601Hemoglobinuria, Paroxysmal · Colombia, Hong Kong, Malaysia and more | 3 | Completed | Jun 23, 2021 | 53 |
| NCT03777332Geographic Atrophy · United States | 1 | Completed | Apr 1, 2021 | 19 |
| NCT03593200Hemoglobinuria, Paroxysmal · Bulgaria, Serbia | 2 | Completed | Oct 22, 2019 | 4 |
| NCT03531255PNH · United States, Australia, Belgium and more | 3 | Completed | Sep 4, 2025 | 137 |
| NCT03525613Geographic Atrophy · United States, Australia, Brazil and more | 3 | Completed | Jun 28, 2021 | 637 |
| NCT03525600Geographic Atrophy · United States, Argentina, Australia and more | 3 | Completed | Jun 21, 2021 | 621 |
| NCT03500549Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more | 3 | Completed | Nov 14, 2019 | 80 |
| NCT03465709Neovascular Age-related Macular Degeneration · United States | 2 | Terminated | Apr 5, 2019 | 17 |
| NCT03453619Glomerulonephritis, IGA · United States | 2 | Completed | Apr 16, 2020 | 21 |
| NCT03226678Anemia, Hemolytic, Autoimmune · United States | 2 | Completed | Sep 12, 2022 | 24 |
| NCT02588833Hemoglobinuria, Paroxysmal · Hong Kong, Malaysia, New Zealand and more | 1 | Completed | Aug 26, 2019 | 23 |
| NCT02503332Geographic Atrophy · United States, Australia, New Zealand | 2 | Completed | Jul 14, 2017 | 246 |
| NCT02461771Neovascular Age-Related Macular Degeneration · United States, Australia | 1 | Completed | Mar 8, 2016 | 13 |
| NCT02264639Hemoglobinuria, Paroxysmal · United States | 1 | Completed | Oct 22, 2018 | 9 |
How it is read
Names in the registry
- “Pegcetacoplan”, 17 entries
- “APL-2”, 7 entries
- “PEGCETACOPLAN (APL-2)”, 2 entries
- “APL-3007, pegcetacoplan (APL-2)”, 2 entries
- “Syfovre™”, 1 entry
Conditions, from the studies’ own filings
- Geographic Atrophy, 9 studies
- Hemoglobinuria, Paroxysmal, 6 studies
- Glomerulonephritis, Membranoproliferative, 4 studies
- Anemia, Hemolytic, Autoimmune, 2 studies
- Macular Degeneration, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.